Clinical Studies

      Prefatory Study to Explore Changes in Nasal Mucociliary Clearance and to Standardize Nasal Scraping Procedure

      First posted
      Mar 22, 2017
      Identifier
      NCT03086707
      Publication Site URL
      Topic
      Official Title

      A 2-arm, Open Label, Prefatory Study to Explore Changes in Nasal Mucociliary Clearance Between Smokers and Never Smokers and to Standardize Nasal Scraping Procedure

      Brief Summary

      This study intends to evaluate the nasal mucociliary clearance (NMC) by determining the value obtained for saccharin transit time (STT) test over the course of 12 hours following a single cigarette use in smokers, to compare it relative to never smokers, and to examine the relationship between plasma nicotine levels and STT value in smokers and never smokers. Safety will also be monitored during the study.The planned maximum study duration for a single study participant from Screening through completion of study will be 33 days.

      Summary

      Recruitment: Completed

      Study Results: Available

      Enrollment: 14

      Study Type: Interventional

      Other IDs: P1-CMS-01-US

      Related Publications

      Influence of tobacco smoking on the development of halitosis

      Clinical

      Tobacco harm reduction: The potential to reduce the risk from smoking: a six-month exposure response study on switching from cigarettes to tobacco heating system (THS)

      Clinical

      Methodology for monitoring adverse event reports for potential modified risk tobacco products: Experience at Philip Morris International

      Clinical

      Biomarker of exposure level data set in smokers switching from conventional cigarettes to Tobacco Heating System 2.2, continuing smoking or abstaining from smoking for 5 days

      Clinical

      Evaluation of biological and functional changes in healthy smokers after switching from cigarettes to Tobacco Heating System (THS) 2.2 for 6 months

      Clinical

      Evaluation of biological and functional changes in healthy smokers switching to the Tobacco Heating System 2.2 versus continued tobacco smoking: Protocol for a randomized, controlled, multicenter study

      Clinical

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.